TY - JOUR
T1 - Myocarditis, Pulmonary Hemorrhage, and Extensive Myositis with Rhabdomyolysis 12 Days After First Dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine
T2 - A Case Report
AU - Al-Rasbi, Sara
AU - Al-Maqbali, Juhaina Salim
AU - Al-Farsi, Rajaa
AU - Al Shukaili, Moza Ali
AU - Al-Riyami, Maryam H
AU - Al Falahi, Zubaida
AU - Al Farhan, Hatem
AU - Al Alawi, Abdullah M
N1 - Publisher Copyright:
© Am J Case Rep, 2022.
PY - 2022/1/11
Y1 - 2022/1/11
N2 - Objective: Background: Case Report: Conclusions: Unusual clinical course The COVID-19 pandemic is a current global crisis, and there are hundreds of millions of individuals being vac-cinated worldwide. At present, there have been few reports of COVID-19 vaccine-induced autoimmune pro-cesses manifested as myositis, thrombocytopenia, and myocarditis. A 37-year-old man presented to the Emergency Department (ED) with a 3-day history of back pain and a 1-day history of left upper limb swelling with paresthesia and shortness of breath, 12-days after receiving the first dose of Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine. He was diagnosed with severe myositis compli-cated with rhabdomyolysis and non-oliguric acute kidney injury, thrombocytopenia, myocarditis with pulmonary edema, and pulmonary hemorrhage. Screens for potential toxic, infectious, paraneoplastic, and autoimmune disorders were unremarkable. The patient was treated with a 5-day course of intravenous methylprednisolone and intravenous immunoglobulin, with a good response. He was hospitalized for 16 days and discharged home on a tapering dose of oral prednisolone for 6 weeks. The case describes a possible link between Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine and immune-mediated myocarditis, pulmonary vasculitis, myositis, and thrombocytopenia. However, further data are re-quired to confirm such an association.
AB - Objective: Background: Case Report: Conclusions: Unusual clinical course The COVID-19 pandemic is a current global crisis, and there are hundreds of millions of individuals being vac-cinated worldwide. At present, there have been few reports of COVID-19 vaccine-induced autoimmune pro-cesses manifested as myositis, thrombocytopenia, and myocarditis. A 37-year-old man presented to the Emergency Department (ED) with a 3-day history of back pain and a 1-day history of left upper limb swelling with paresthesia and shortness of breath, 12-days after receiving the first dose of Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine. He was diagnosed with severe myositis compli-cated with rhabdomyolysis and non-oliguric acute kidney injury, thrombocytopenia, myocarditis with pulmonary edema, and pulmonary hemorrhage. Screens for potential toxic, infectious, paraneoplastic, and autoimmune disorders were unremarkable. The patient was treated with a 5-day course of intravenous methylprednisolone and intravenous immunoglobulin, with a good response. He was hospitalized for 16 days and discharged home on a tapering dose of oral prednisolone for 6 weeks. The case describes a possible link between Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine and immune-mediated myocarditis, pulmonary vasculitis, myositis, and thrombocytopenia. However, further data are re-quired to confirm such an association.
KW - Adult
KW - BNT162 Vaccine
KW - COVID-19
KW - COVID-19 Vaccines
KW - Hemorrhage
KW - Humans
KW - Male
KW - Myocarditis/diagnosis
KW - Myositis/chemically induced
KW - Pandemics
KW - RNA, Messenger
KW - Rhabdomyolysis/complications
KW - SARS-CoV-2
KW - Thrombocytopenia
KW - COVID-19 Vaccine
KW - Myocarditis
KW - Myositis
UR - http://www.scopus.com/inward/record.url?scp=85124620659&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85124620659&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/2067e644-e5a7-3dad-823b-f745b5a2db83/
U2 - 10.12659/AJCR.934399
DO - 10.12659/AJCR.934399
M3 - Article
C2 - 35173141
SN - 1941-5923
VL - 23
SP - e934399
JO - American Journal of Case Reports
JF - American Journal of Case Reports
IS - 1
M1 - e934399
ER -
